Search for more clinical trials
Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
Conditions
Thyroid Cancer
Conditions: official terms
Thyroid Diseases - Thyroid Neoplasms
Conditions: Keywords
Thyroid carcinoma, predictive factors, refractory, Differentiated, follicular origin
Study Type
Interventional
Study Phase
N/A
Study Design
Intervention Model: Single Group Assignment, Masking: Open Label
Intervention
Name: follow up visit
Type: Other
Overall Status
Recruiting
Summary
It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %.
The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.
The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:
- Man or woman ≥ 18 years.
- Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly differentiated carcinoma).
- TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.
- Patient after post operative radioiodine therapy.
Exclusion Criteria:
- Patient who can not be followed during the protocol.
- Patient who does not consent.
- Man or woman ≥ 18 years.
- Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly differentiated carcinoma).
- TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.
- Patient after post operative radioiodine therapy.
Exclusion Criteria:
- Patient who can not be followed during the protocol.
- Patient who does not consent.
Location
Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel
Bron cedex, France
Status: Recruiting
Contact: Claire BOURNAUD, MD - +33472356999 - claire.bournaud-salinas@chu-lyon.fr
Start Date
May 2012
Completion Date
May 2022
Sponsors
Hospices Civils de Lyon
Source
Hospices Civils de Lyon
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page